Francesco Massari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/706538/publications.pdf

Version: 2024-02-01

453	8,189	53660	98622
papers	citations	45 h-index	67 g-index

461	461	461	10831
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern Pathology, 2018, 31, 24-38.	2.9	324
2	Metabolic phenotype of bladder cancer. Cancer Treatment Reviews, 2016, 45, 46-57.	3.4	201
3	PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treatment Reviews, 2015, 41, 114-121.	3.4	161
4	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
5	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers, 2021, 13, 131.	1.7	153
6	ARTS (Aspirationâ€“Retriever Technique for Stroke): Initial clinical experience. Interventional Neuroradiology, 2016, 22, 325-332.	0.7	144
7	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Frontiers in Pharmacology, 2016, 7, 376.	1.6	127
8	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget, 2016, 7, 54564-54571.	0.8	116
9	The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future Oncology, 2020, 16, 2029-2033.	1.1	113
10	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2013, 62, 1757-1768.	2.0	110
11	Epigenetic modulations and lineage plasticity in advanced prostate cancer. Annals of Oncology, 2020, 31, 470-479.	0.6	103
12	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells, 2020, 9, 2653.	1.8	98
13	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Annals of Oncology, 2015, 26, 2107-2113.	0.6	85
14	BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics, 2015, 15, 1201-1210.	1.5	78
15	Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anti-Cancer Drugs, 2013, 24, 535-554.	0.7	77
16	Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treatment Reviews, 2018, 64, 11-20.	3.4	76
17	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Critical Reviews in Oncology/Hematology, 2022, 170, 103596.	2.0	76
18	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. European Urology, 2015, 68, 147-153.	0.9	73

#	Article	IF	Citations
19	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	0.7	72
20	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers, 2020, 12, 1449.	1.7	72
21	Metabolic alterations in renal cell carcinoma. Cancer Treatment Reviews, 2015, 41, 767-776.	3.4	71
22	Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 154, 120-127.	1.3	71
23	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	3.5	65
24	Is There a Role for Immunotherapy in Prostate Cancer?. Cells, 2020, 9, 2051.	1.8	65
25	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. Expert Opinion on Investigational Drugs, 2022, 31, 371-378.	1.9	65
26	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Critical Reviews in Oncology/Hematology, 2015, 96, 81-90.	2.0	64
27	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treatment Reviews, 2017, 54, 68-73.	3.4	64
28	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2020, 19, 1329-1338.	1.0	64
29	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. European Urology Focus, 2022, 8, 514-521.	1.6	64
30	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-8.	1.0	63
31	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	5.1	61
32	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Targeted Oncology, 2022, 17, 61-68.	1.7	61
33	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. European Journal of Cancer, 2013, 49, 2134-2142.	1.3	60
34	Safety, efficacy, and short-term follow-up of the use of Pipelineâ„¢ Embolization Device in small (<2.5mm) cerebral vessels for aneurysm treatment: single institution experience. Neuroradiology, 2016, 58, 267-275.	1.1	59
35	Role of STAT3 pathway in genitourinary tumors. Future Science OA, 2015, 1, FSO15.	0.9	58
36	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.2	58

#	Article	IF	Citations
37	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 2016, 11, 345-351.	1.7	56
38	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews, 2017, 55, 71-82.	3.4	56
39	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. European Urology, 2015, 68, 154-160.	0.9	53
40	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. Frontiers in Oncology, 2018, 8, 653.	1.3	53
41	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. Tumori, 2017, 103, 405-421.	0.6	52
42	CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors. BioMed Research International, 2014, 2014, 1-12.	0.9	51
43	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology, 2015, 10, 517-522.	1.7	49
44	AR-V7 and prostate cancer: The watershed for treatment selection?. Cancer Treatment Reviews, 2016, 43, 27-35.	3.4	49
45	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. International Journal of Cancer, 2015, 136, 1-10.	2.3	47
46	Immune checkpoint inhibitors and prostate cancer: a new frontier?. Oncology Reviews, 2016, 10, 293.	0.8	47
47	Percutaneous Vertebroplasty in Multiple Myeloma Vertebral Involvement. Journal of Spinal Disorders and Techniques, 2008, 21, 344-348.	1.8	46
48	The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews, 2016, 49, 37-44.	3.4	46
49	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 57-75.	1.5	46
50	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. PLoS ONE, 2016, 11, e0158952.	1.1	45
51	PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT).. Journal of Clinical Oncology, 2012, 30, 4541-4541.	0.8	45
52	Percutaneous vertebroplasty in 1,253 levels: results and long-term effectiveness in a single centre. European Radiology, 2009, 19, 165-171.	2.3	44
53	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. Expert Opinion on Investigational Drugs, 2015, 24, 809-824.	1.9	43
54	Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 152-159.	1.6	43

#	Article	IF	Citations
55	Vertebroplasty and Kyphoplasty in the Treatment of Malignant Vertebral Fractures. Journal of Chemotherapy, 2004, 16, 30-33.	0.7	42
56	Diagnostic and Therapeutic Joint Injections. Seminars in Interventional Radiology, 2010, 27, 160-171.	0.3	42
57	The Identification of Immunological Biomarkers in Kidney Cancers. Frontiers in Oncology, 2018, 8, 456.	1.3	40
58	Distal radial access in the anatomical snuffbox for neurointerventions: a feasibility, safety, and proof-of-concept study. Journal of NeuroInterventional Surgery, 2020, 12, 798-801.	2.0	40
59	Interleukin-Ibeta and Beta-Endorphin Orcadian Rhythms are Inversely Related in Normal and Stress-Altered Sleep. International Journal of Neuroscience, 1992, 63, 299-305.	0.8	39
60	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. Immunotherapy, 2018, 10, 1229-1239.	1.0	38
61	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy, 2019, 11, 631-643.	1.0	38
62	The Human Microbiota and Prostate Cancer: Friend or Foe?. Cancers, 2019, 11, 459.	1.7	38
63	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells, 2019, 8, 43.	1.8	38
64	Treating Prostate Cancer by Antibodyâ€“Drug Conjugates. International Journal of Molecular Sciences, 2021, 22, 1551.	1.8	38
65	FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. Journal of Experimental and Clinical Cancer Research, 2012, 31, 103.	3.5	37
66	Endovascular reconstruction of unruptured intradural vertebral artery dissecting aneurysms with the Pipeline embolization device. Journal of NeuroInterventional Surgery, 2016, 8, 1048-1051.	2.0	37
67	Nucleoplasty in the Treatment of Lumbar Diskogenic Back Pain: One Year Follow-Up. CardioVascular and Interventional Radiology, 2007, 30, 426-432.	0.9	36
68	Adjuvant therapy in renal cell carcinoma. Cancer Treatment Reviews, 2017, 60, 152-157.	3.4	35
69	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Targeted Oncology, 2018, 13, 705-714.	1.7	35
70	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells, 2020, 9, 1073.	1.8	34
71	Towards a new WHO classification of renal cell tumor: what the clinician needs to knowâ€”a narrative review. Translational Andrology and Urology, 2021, 10, 1506-1520.	0.6	34
72	Radiofrequency Heat Ablation and Vertebroplasty in the treatment of neoplastic vertebral body fractures. Anticancer Research, 2004, 24, 3129-33.	0.5	34

#	Article	IF	Citations
73	On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. Annals of Oncology, 2020, 31, 1415-1416.	0.6	32
74	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. Oncotarget, 2017, 8, 100708-100716.	0.8	32
75	Percutaneous Vertebroplasty in Painful Schmorl Nodes. CardioVascular and Interventional Radiology, 2006, 29, 97-101.	0.9	31
76	Use of the Pipeline embolization device for recurrent and residual cerebral aneurysms: a safety and efficacy analysis with short-term follow-up. Journal of NeuroInterventional Surgery, 2017, 9, 1208-1213.	2.0	31
77	Two-year single-center experience with the â€˜Baby Trevoâ€™ stent retriever for mechanical thrombectomy in acute ischemic stroke. Journal of NeuroInterventional Surgery, 2017, 9, 541-546.	2.0	31
78	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or PoorÂPrognosis?. Clinical Genitourinary Cancer, 2018, 16, 355-359.e1.	0.9	31
79	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. Current Drug Metabolism, 2017, 18, 712-722.	0.7	31
80	Increased Spontaneous Release of Tumor Necrosis Factor-Î±/Cachectin in Headache Patients. A Possible Correlation with Plasma Endotoxin and Hypothalamic-Pituitary-Adrenal Axis. International Journal of Neuroscience, 1991, 61, 53-60.	0.8	30
81	The origin of prostate metastases: emerging insights. Cancer and Metastasis Reviews, 2015, 34, 765-773.	2.7	30
82	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. European Journal of Cancer, 2017, 83, 237-246.	1.3	30
83	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clinical Genitourinary Cancer, 2018, 16, e945-e951.	0.9	30
84	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers, 2019, 11, 830.	1.7	29
85	Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 401-414.	1.5	28
86	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant ProstateÂCancer: Meta-Analysis of Efficacy and Safety Outcomes. Clinical Genitourinary Cancer, 2019, 17, e871-e877.	0.9	28
87	Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials. Clinical Genitourinary Cancer, 2019, 17, e339-e344.	0.9	28
88	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. Journal of Clinical Pathology, 2019, 72, 135-139.	1.0	28
89	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Targeted Oncology, 2020, 15, 495-501.	1.7	28
90	Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2021, 13, 257-270.	1.0	28

#	Article	IF	Citations
91	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget, 2015, 6, 32161-32168.	0.8	28
92	Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. Journal of Experimental and Clinical Cancer Research, 2011, 30, 115.	3.5	27
93	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer and Metastasis Reviews, 2014, 33, 321-331.	2.7	27
94	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treatment Reviews, 2018, 68, 80-85.	3.4	27
95	Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors. Journal of Clinical Oncology, 2020, 38, 105-106.	0.8	27
96	Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers, 2021, 13, 546.	1.7	27
97	MRI and bone scan imaging in the preoperative evaluation of painful vertebral fractures treated with vertebroplasty and kyphoplasty. In Vivo, 2005, 19, 1055-60.	0.6	27
98	Sacroplasty and Iliac Osteoplasty Under Combined CT and Fluoroscopic Guidance. Spine, 2006, 31, E667-E669.	1.0	26
99	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clinical Drug Investigation, 2019, 39, 503-519.	1.1	26
100	Three-Year Results of Repaired Barlow Mitral Valves via Right Minithoracotomy versus Median Sternotomy in a Randomized Trial. Cardiology, 2014, 128, 97-105.	0.6	25
101	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. Current Drug Metabolism, 2017, 18, 700-711.	0.7	25
102	The immunocheckpoints in modern oncology: the next 15 years. Expert Opinion on Biological Therapy, 2015, 15, 917-921.	1.4	24
103	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Review of Molecular Diagnostics, 2020, 20, 231-243.	1.5	24
104	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 1367-1369.	1.1	23
105	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers, 2019, 11, 196.	1.7	23
106	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer, 2021, 19, e84-e91.	0.9	23
107	Microbiota and prostate cancer. Seminars in Cancer Biology, 2022, 86, 1058-1065.	4.3	23
108	Adjuvant Treatment for Resected Renal Cell Carcinoma: Are All Strategies Equally Negative? Potential Implications for Trial Design With Targeted Agents. Clinical Genitourinary Cancer, 2013, 11, 471-476.	0.9	22

#	Article	IF	Citations
109	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology, 2015, 96, 206-219.	2.0	22
110	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs, 2016, 30, 263-273.	2.2	22
111	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers, 2020, 12, 84.	1.7	22
112	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. PLoS ONE, 2015, 10, e0127908.	1.1	21
113	Use of self-expanding stents for better intracranial flow diverter wall apposition. Interventional Neuroradiology, 2017, 23, 129-136.	0.7	21
114	Cabozantinibâ€related cardiotoxicity: a prospective analysis in a realâ€world cohort of metastatic renal cell carcinoma patients. British Journal of Clinical Pharmacology, 2019, 85, 1283-1289.	1.1	21
115	Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. British Journal of Cancer, 2013, 109, 686-693.	2.9	20
116	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. Current Drug Targets, 2016, 17, 771-776.	1.0	20
117	The Tumor Entity Denominated â€œclear cell-papillary renal cell carcinomaâ€•According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. Pathology and Oncology Research, 2018, 24, 447-456.	0.9	20
118	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Frontiers in Oncology, 2018, 8, 397.	1.3	20
119	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Review of Molecular Diagnostics, 2018, 18, 645-655.	1.5	20
120	BAP1 in solid tumors. Future Oncology, 2019, 15, 2151-2162.	1.1	20
121	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Frontiers in Oncology, 2019, 9, 228.	1.3	20
122	Microbiome and Cancers, With Focus on Genitourinary Tumors. Frontiers in Oncology, 2019, 9, 178.	1.3	20
123	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 42-45.	0.6	20
124	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	3.4	19
125	Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. Future Oncology, 2015, 11, 1809-1828.	1.1	19
126	Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget, 2017, 8, 7328-7335.	0.8	19

#	Article	IF	Citations
127	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 685-693.	1.1	19
128	Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. European Journal of Cancer, 2020, 138, 202-211.	1.3	19
129	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist, 2021, 26, 740-750.	1.9	19
130	Metabolic Alterations in Renal and Prostate Cancer. Current Drug Metabolism, 2016, 17, 150-155.	0.7	19
131	Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers, 2022, 14, 1245.	1.7	19
132	Percutaneous vertebroplasty in the management of vertebral osteoporotic fractures. Short-term, mid-term and long-term follow-up of 285 patients. Skeletal Radiology, 2009, 38, 863-869.	1.2	18
133	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori, 2013, 99, 637-649.	0.6	18
134	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 129, 124-132.	2.0	18
135	Bladder Cancer: Molecular Determinants of Personalized Therapy. Current Drug Targets, 2015, 16, 115-124.	1.0	18
136	Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocrine-Related Cancer, 2009, 16, 1241-1249.	1.6	17
137	Lung Adenocarcinoma Patient Refractory to Gefitinib and Responsive to Crizotinib, with Concurrent Rare Mutation of the Epidermal Growth Factor Receptor (L861Q) and Increased ALK/MET/ROS1 Gene Copy Number. Journal of Thoracic Oncology, 2013, 8, e105-e106.	0.5	17
138	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the <scp>I</scp>talian Named Patient Programme. BJU International, 2015, 115, 764-771.	1.3	17
139	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy, 2019, 11, 1507-1521.	1.0	17
140	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e83-e90.	0.9	17
141	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clinical Genitourinary Cancer, 2021, 19, 32-40.	0.9	17
142	Quality of life assessment in renal cell carcinomaÂPhase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncology, 2021, 17, 2671-2681.	1.1	17
143	Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A â€˜Hard Days Night'. Current Pharmaceutical Design, 2014, 20, 3958-3972.	0.9	17
144	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. European Urology Focus, 2022, 8, 1696-1702.	1.6	17

#	Article	IF	Citations
145	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. Future Oncology, 2015, 11, 107-119.	1.1	16
146	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. Clinical Genitourinary Cancer, 2016, 14, e161-e169.	0.9	16
147	Pipeline Embolization Device for Pericallosal Artery Aneurysms: A Retrospective Single Center Safety and Efficacy Study. Operative Neurosurgery, 2018, 14, 351-358.	0.4	16
148	Tivozanib for the treatment of renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2018, 19, 1021-1025.	0.9	16
149	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunotherapy, 2020, 12, 151-159.	1.0	16
150	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. Targeted Oncology, 2016, 11, 569-577.	1.7	15
151	Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2019, 142, 141-152.	2.0	15
152	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. Cancers, 2019, 11, 1225.	1.7	15
153	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: Whatâ€™s the Story Morning Glory?. International Journal of Molecular Sciences, 2021, 22, 6237.	1.8	15
154	Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188547.	3.3	15
155	The route to personalized medicine in bladder cancer: where do we stand?. Targeted Oncology, 2015, 10, 325-336.	1.7	14
156	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. Critical Reviews in Oncology/Hematology, 2015, 93, 50-59.	2.0	14
157	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Clinical Genitourinary Cancer, 2016, 14, 48-55.	0.9	14
158	Circulating tumor cells in genitourinary tumors. Therapeutic Advances in Urology, 2018, 10, 65-77.	0.9	14
159	²²³Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. Tumori, 2018, 104, 128-136.	0.6	14
160	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Review of Molecular Diagnostics, 2020, 20, 255-264.	1.5	14
161	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 141-150.	1.5	14
162	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Review of Anticancer Therapy, 2020, 20, 755-763.	1.1	14

#	Article	IF	Citations
163	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. Expert Review of Anticancer Therapy, 2020, 20, 491-501.	1.1	14
164	The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. Cardiovascular Drugs and Therapy, 2021, 35, 505-519.	1.3	14
165	Epigenetic Modifications and Modulators in Prostate Cancer. Critical Reviews in Oncogenesis, 2017, 22, 439-450.	0.2	14
166	Percutaneous kyphoplasty: new treatment for painful vertebral body fractures. In Vivo, 2004, 18, 149-53.	0.6	14
167	Percutaneous ethanol embolization and cement augmentation of aggressive vertebral hemangiomas at two adjacent vertebral levels. Journal of Neuroradiology, 2014, 41, 269-274.	0.6	13
168	Future perspectives for personalized immunotherapy in renal cell carcinoma. Expert Opinion on Biological Therapy, 2017, 17, 1049-1052.	1.4	13
169	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. Archives of Pathology and Laboratory Medicine, 2017, 141, 1460-1461.	1.2	13
170	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. European Urology Focus, 2021, 7, 955-963.	1.6	13
171	Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Clinical Drug Investigation, 2020, 40, 211-226.	1.1	13
172	An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opinion on Investigational Drugs, 2021, 30, 245-251.	1.9	13
173	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. Diagnostics, 2021, 11, 138.	1.3	13
174	An Overview of Emerging Immunotargets of Genitourinary Tumors. Current Drug Targets, 2016, 17, 750-756.	1.0	13
175	Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis. American Journal of Clinical Pathology, 2022, 157, 644-648.	0.4	13
176	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences, 2021, 22, 13519.	1.8	13
177	True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs. PLoS ONE, 2012, 7, e49689.	1.1	12
178	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2014, 90, 135-145.	2.0	12
179	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncology, 2015, 11, 2881-2891.	1.1	12
180	Onyx embolization in distal dissecting posterior inferior cerebellar artery aneurysms. Journal of NeuroInterventional Surgery, 2016, 8, 501-506.	2.0	12

#	Article	IF	Citations
181	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. International Journal of Molecular Sciences, 2021, 22, 5522.	1.8	12
182	Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1237-1243.	1.5	12
183	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. Current Drug Targets, 2020, 21, 1664-1671.	1.0	12
184	Retreatment of Residual and Recurrent Aneurysms After Embolization With the Woven EndoBridge Device: Multicenter Case Series. Neurosurgery, 2022, 90, 569-580.	0.6	12
185	Intracranial atheromatous disease treatment with the Wingspan stent system: Evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid-term results. Clinical Neurology and Neurosurgery, 2013, 115, 741-747.	0.6	11
186	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 1905-1910.	0.2	11
187	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. Immunotherapy, 2017, 9, 579-587.	1.0	11
188	Atezolizumab for platinum-treated metastatic urothelial carcinoma. Lancet, The, 2018, 391, 716-718.	6.3	11
189	Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. Cancer Genetics, 2020, 248-249, 57-62.	0.2	11
190	Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. Future Oncology, 2020, 16, 75-80.	1.1	11
191	Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. Translational Andrology and Urology, 2021, 10, 1521-1529.	0.6	11
192	Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1225-1232.	1.4	11
193	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget, 2016, 7, 33381-33390.	0.8	11
194	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. Current Drug Metabolism, 2019, 20, 305-312.	0.7	11
195	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncology, 2022, 18, 739-748.	1.1	11
196	Future directions in percutaneous vertebroplasty. Radiologia Medica, 2009, 114, 976-983.	4.7	10
197	Present and future of personalized medicine in adult genitourinary tumors. Future Oncology, 2015, 11, 1381-1388.	1.1	10
198	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. Molecular Diagnosis and Therapy, 2016, 20, 255-263.	1.6	10

#	Article	IF	Citations
199	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 541.e7-541.e13.	0.8	10
200	Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases. International Journal of Biological Markers, 2017, 32, 243-247.	0.7	10
201	Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 751-758.	3.3	10
202	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 526.e13-526.e18.	0.8	10
203	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. Translational Andrology and Urology, 2021, 10, 1530-1540.	0.6	10
204	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. Pathology Research and Practice, 2021, 222, 153440.	1.0	10
205	Emerging Immunotargets and Immunotherapies in Prostate Cancer. Current Drug Targets, 2016, 17, 777-782.	1.0	10
206	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. Current Drug Targets, 2020, 21, 1463-1475.	1.0	10
207	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210795.	1.4	10
208	Combining Percutaneous Pedicular and Extrapedicular Access for Tumor Ablation in a Thoracic Vertebral Body. Interventional Neuroradiology, 2014, 20, 603-608.	0.7	9
209	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Review of Molecular Diagnostics, 2017, 17, 781-789.	1.5	9
210	Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. Anti-Cancer Drugs, 2018, 29, 710-715.	0.7	9
211	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. Molecular Diagnosis and Therapy, 2019, 23, 569-577.	1.6	9
212	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. Annals of Translational Medicine, 2019, 7, S137-S137.	0.7	9
213	Immunotherapy for urothelial cancer: from the diagnostic pathologistâ€™s point of view. Expert Opinion on Biological Therapy, 2020, 20, 539-544.	1.4	9
214	Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. Cancers, 2021, 13, 3471.	1.7	9
215	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opinion on Biological Therapy, 2020, 20, 1047-1059.	1.4	9
216	Emerging Immunotargets in Bladder Cancer. Current Drug Targets, 2016, 17, 757-770.	1.0	9

#	Article	IF	Citations
217	Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma. Chinese Clinical Oncology, 2019, 8, S21-S21.	0.4	9
218	Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Critical Reviews in Oncology/Hematology, 2022, 176, 103731.	2.0	9
219	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncology, 2016, 12, 493-502.	1.1	8
220	Republished: Monotherapy with stenting in subarachnoid hemorrhage (SAH) after middle cerebral artery dissection. Journal of NeuroInterventional Surgery, 2016, 8, e13-e13.	2.0	8
221	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 39-43.	0.6	8
222	The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 169-175.	0.4	8
223	Renal cell carcinoma in one year: Going inside the news of 2017 â€“ A report of the main advances in RCC cancer research. Cancer Treatment Reviews, 2018, 67, 29-33.	3.4	8
224	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells, 2020, 9, 1495.	1.8	8
225	Utilization of a New Intracranial Support Catheter as an Intermediate Aspiration Catheter in the Treatment of Acute Ischemic Stroke: Technical Report on Initial Experience. Cureus, 2016, 8, e617.	0.2	8
226	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: Whatâ€™s Now, Whatâ€™s New, and Whatâ€™s Coming?. Cancers, 2022, 14, 907.	1.7	8
227	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer, 2022, 172, 191-198.	1.3	8
228	The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. Expert Review of Anticancer Therapy, 2016, 16, 681-696.	1.1	7
229	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: â€˜Game Overâ€™?. Targeted Oncology, 2016, 11, 431-446.	1.7	7
230	Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?. Future Oncology, 2018, 14, 2997-2999.	1.1	7
231	Overview on Percutaneous Therapies of Disc Diseases. Medicina (Lithuania), 2019, 55, 471.	0.8	7
232	Avelumab Maintenance for Urothelial Carcinoma. New England Journal of Medicine, 2020, 383, 2482-2483.	13.9	7
233	Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach. European Journal of Cancer, 2021, 143, 75-77.	1.3	7
234	Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy, 2021, 13, 685-692.	1.0	7

#	Article	IF	Citations
235	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. Current Drug Metabolism, 2017, 18, 692-699.	0.7	7
236	Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 872-886.	0.9	7
237	Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. Cancers, 2021, 13, 5229.	1.7	7
238	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1455-1466.	1.5	7
239	Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?. Anticancer Research, 2022, 42, 1487-1493.	0.5	7
240	Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current Oncology, 2022, 29, 1709-1722.	0.9	7
241	The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis. Journal of Personalized Medicine, 2022, 12, 842.	1.1	7
242	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. Expert Opinion on Pharmacotherapy, 2013, 14, 597-608.	0.9	6
243	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2015, 9, 263.	0.3	6
244	Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-Î± Co-amplification asÂPredictors of Pathologic Complete Response toÂNeoadjuvant Chemotherapy With Trastuzumab and Docetaxel. Clinical Breast Cancer, 2015, 15, 16-23.	1.1	6
245	Clinical outcomes in a contemporary series of â€œyoungâ€•patients with castration-resistant prostate cancer who were 60 years and younger. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 265.e15-265.e21.	0.8	6
246	Immunotargeting and personalized therapies in genitourinary cancers. Future Oncology, 2016, 12, 1853-1856.	1.1	6
247	Longâ€term clinical impact of PSA surge in castrationâ€resistant prostate cancer patients treated with abiraterone. Prostate, 2017, 77, 1012-1019.	1.2	6
248	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738â€“9. European Urology, 2017, 71, e73-e75.	0.9	6
249	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncology, 2018, 14, 2559-2564.	1.1	6
250	Re: Arnaud MÃ©jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417â€“27. European Urology Oncology, 2019, 2, 340-341.	2.6	6
251	Prostate cancer pathology: What has changed in the last 5 years. Urologia, 2020, 87, 3-10.	0.3	6
252	Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy, 2020, 12, 1257-1268.	1.0	6

#	Article	IF	Citations
253	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. Cells, 2020, 9, 1522.	1.8	6
254	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€"a narrative review. Translational Andrology and Urology, 2021, 10, 1541-1552.	0.6	6
255	Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 45-51.	0.7	6
256	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncology, 2021, 16, 625-632.	1.7	6
257	Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.. Journal of Clinical Oncology, 2014, 32, 5089-5089.	0.8	6
258	Adenocarcinoma of the paraurethral glands: a case report. Histology and Histopathology, 2014, 29, 1295-303.	0.5	6
259	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. Current Oncology, 2022, 29, 3499-3518.	0.9	6
260	Incidence of grade 3â€"4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 235-240.	1.5	6
261	Kyphoplasty. American Journal of Physical Medicine and Rehabilitation, 2004, 83, 810-812.	0.7	5
262	Continuous i.v. infusion of remifentanil and intraosseous lidocaine provide better analgesia than intraosseous lidocaine alone in percutaneous vertebroplasty of osteoporotic fractures. British Journal of Anaesthesia, 2009, 103, 901-902.	1.5	5
263	Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. Expert Review of Anticancer Therapy, 2015, 15, 1037-1048.	1.1	5
264	Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3. Future Oncology, 2016, 12, 1431-1433.	1.1	5
265	Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560â€"9. European Urology, 2018, 74, e118-e119.	0.9	5
266	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 529.e1-529.e7.	0.8	5
267	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Expert Review of Molecular Diagnostics, 2020, 20, 207-217.	1.5	5
268	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. Journal of Clinical Medicine, 2020, 9, 1351.	1.0	5
269	Cabazitaxel in Metastatic Prostate Cancer. New England Journal of Medicine, 2020, 382, 1286-1286.	13.9	5
270	Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218. European Urology Oncology, 2020, 3, 561-562.	2.6	5

#	Article	IF	Citations
271	Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis. Diagnostics, 2020, 10, 123.	1.3	5
272	Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	5
273	A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34. Pathology Research and Practice, 2021, 227, 153637.	1.0	5
274	Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.. Journal of Clinical Oncology, 2020, 38, 751-751.	0.8	5
275	Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma. Tumori, 2004, 90, 22-6.	0.6	5
276	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clinical Genitourinary Cancer, 2022, 20, 285-295.	0.9	5
277	Current androgen receptor antagonists under investigation for resistant prostate cancer. Expert Review of Anticancer Therapy, 2022, 22, 191-202.	1.1	5
278	Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy. Cancer Management and Research, 0, Volume 14, 1945-1960.	0.9	5
279	Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer, 2011, 73, 78-88.	0.9	4
280	Clinical meta-analyses of targeted therapies in adenocarcinoma. Targeted Oncology, 2013, 8, 35-45.	1.7	4
281	Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. Pathology, 2014, 46, 523-526.	0.3	4
282	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). Current Drug Targets, 2016, 17, 748-749.	1.0	4
283	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. Future Oncology, 2017, 13, 1105-1114.	1.1	4
284	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. European Urology Supplements, 2017, 16, 223-231.	0.1	4
285	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). ESMO Open, 2018, 3, e000389.	2.0	4
286	Comparison and optimization of genetic tools used for the identification of ancient fish remains recovered from archaeological excavations and museum collections in the Mediterranean region. International Journal of Osteoarchaeology, 2019, 29, 365-376.	0.6	4
287	Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353â€“66. European Urology Oncology, 2020, 3, 390.	2.6	4
288	Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065. European Urology, 2020, 78, e205-e206.	0.9	4

#	Article	IF	Citations
289	Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer. Pathology Research and Practice, 2020, 216, 153012.	1.0	4
290	Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125â€“35. European Urology Oncology, 2021, 4, 670.	2.6	4
291	Morphology and Species Composition of Southern Adriatic Sea Leptocephali Evaluated Using DNA Barcoding. PLoS ONE, 2016, 11, e0166137.	1.1	4
292	PD-L1 Inhibitors for the Treatment of Prostate Cancer. Current Drug Targets, 2020, 21, 1558-1565.	1.0	4
293	Ancient DNA SNP-panel data suggests stability in bluefin tuna genetic diversity despite centuries of fluctuating catches in the eastern Atlantic and Mediterranean. Scientific Reports, 2021, 11, 20744.	1.6	4
294	Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anti-Cancer Drugs, 2021, 32, 74-81.	0.7	4
295	Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. American Journal of Cancer Research, 2014, 4, 907-15.	1.4	4
296	Risk of toxicity with immunotherapyâ€“tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future Oncology, 2022, 18, 625-634.	1.1	4
297	Super large-bore ingestion of clot (SLIC) leads to high first pass effect in thrombectomy for large vessel occlusion. Journal of NeuroInterventional Surgery, 2023, 15, 664-668.	2.0	4
298	Is 3T-MR Spectroscopy a Predictable Selection Tool in Prophylactic Vertebroplasty?. CardioVascular and Interventional Radiology, 2010, 33, 1243-1252.	0.9	3
299	Acute stroke treatment using the Penumbra endovascular mechanical thrombolysis device: a single-centre experience. Radiologia Medica, 2012, 117, 1199-1214.	4.7	3
300	Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?. European Urology, 2016, 69, 969-970.	0.9	3
301	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. European Urology Supplements, 2017, 16, 232-240.	0.1	3
302	Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405â€“15. European Urology, 2018, 74, e50.	0.9	3
303	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. Future Oncology, 2018, 14, 2691-2699.	1.1	3
304	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy, 2019, 17, 917-927.	0.6	3
305	CheckMate 214 patient-reported outcomes: listening to our patients. Lancet Oncology, The, 2019, 20, 179-180.	5.1	3
306	Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers. Diagnostics, 2020, 10, 1109.	1.3	3

#	Article	IF	Citations
307	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. Journal of Clinical Medicine, 2020, 9, 1950.	1.0	3
308	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. Translational Andrology and Urology, 2021, 10, 1581-1587.	0.6	3
309	Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. Pathology Research and Practice, 2021, 219, 153350.	1.0	3
310	Expected and non-expected immune-related adverse events detectable by CT. European Journal of Radiology, 2021, 138, 109617.	1.2	3
311	A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?. Future Oncology, 2021, 17, 1839-1841.	1.1	3
312	Left Ventricular Noncompaction Cardiomyopathy as a Potential Cause of Bilateral Posterior Cerebral Artery Stroke â€“ a Rare and Unique Clinical Occurrence. American Journal of Case Reports, 2021, 22, e931103.	0.3	3
313	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDCÂrisk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy, 2021, 13, 783-793.	1.0	3
314	Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. European Urology, 2021, 79, 887-889.	0.9	3
315	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers, 2021, 13, 3492.	1.7	3
316	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro) Tj ETQq0 0 0 rgBT /Overlock 10	0.9	3
317	Urinary Biomarkers for Prostate Cancer. Current Drug Metabolism, 2017, 18, 723-726.	0.7	3
318	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Therapeutic Advances in Urology, 2021, 13, 175628722110543.	0.9	3
319	Trapped Embolic Protection Device: A Salvage Technique. Cureus, 2020, 12, e9228.	0.2	3
320	Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 1038.	1.0	3
321	Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study. European Urology, 2022, 81, 623-624.	0.9	3
322	Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: aÂmeta-analysis. Immunotherapy, 2022, 14, 617-625.	1.0	3
323	Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis. Clinical Genitourinary Cancer, 2022, 20, 482-487.	0.9	3
324	On the Physiological Significance of Tumor Necrosis Factor-Î± in the Human Amniotic Fluid. Immunopharmacology and Immunotoxicology, 1992, 14, 749-756.	1.1	2

#	Article	IF	Citations
325	Could Migraine Be A â€œProtective Factorâ€•Against Tumors?. International Journal of Neuroscience, 1994, 75, 139-143.	0.8	2
326	Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. Future Science OA, 2015, 1, FSO29.	0.9	2
327	Monotherapy with stenting in subarachnoid hemorrhage (SAH) after middle cerebral artery dissection. BMJ Case Reports, 2015, 2015, bcr2014011596-bcr2014011596.	0.2	2
328	Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. Cellular and Molecular Immunology, 2015, 12, 122-124.	4.8	2
329	Genitourinary Cancers: Molecular Determinants for Personalized Therapies. Urologia, 2016, 83, 107-109.	0.3	2
330	The role of precision medicine for the treatment of metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2016, 1, 369-377.	0.4	2
331	Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 2016, 374, 286-287.	13.9	2
332	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. Critical Reviews in Oncology/Hematology, 2016, 98, 254-263.	2.0	2
333	Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738â€“9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol 2017;71:e73â€“5. European Urology, 2017, 72, e37-e38.	0.9	2
334	Immunotherapy in genitourinary cancers: where are we going?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 73-78.	0.4	2
335	Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62â€“8. European Urology, 2018, 73, e72.	0.9	2
336	A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. Anti-Cancer Drugs, 2018, 29, 911-913.	0.7	2
337	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anti-Cancer Drugs, 2018, 29, 705-709.	0.7	2
338	Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud MÃ©jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842â€“3. European Urology, 2019, 75, e64-e66.	0.9	2
339	New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?. European Urology Oncology, 2019, 2, 471.	2.6	2
340	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. Future Oncology, 2019, 15, 563-565.	1.1	2
341	Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485. European Urology Oncology, 2020, 3, 806.	2.6	2
342	Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.ccr-20-2063. European Urology Oncology, 2020, 3, 804-805.	2.6	2

#	Article	IF	Citations
343	Re: Platinum-based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations. European Urology, 2020, 78, 768-770.	0.9	2
344	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. Translational Andrology and Urology, 2021, 10, 1562-1568.	0.6	2
345	An update on immunotherapy in uro-oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 229-233.	0.4	2
346	Adjuvant immunotherapy in muscle-invasive urothelial carcinoma. Lancet Oncology, The, 2021, 22, e237.	5.1	2
347	A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Anti-Cancer Drugs, 2022, 33, e43-e51.	0.7	2
348	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1-14.	0.9	2
349	Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. Medicines (Basel, Switzerland), 2021, 8, 5.	0.7	2
350	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2015, 33, e16059-e16059.	0.8	2
351	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian Journal of Andrology, 2019, 21, 19.	0.8	2
352	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World Journal of Clinical Oncology, 2021, 12, 1037-1046.	0.9	2
353	Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. Journal of Clinical Medicine, 2021, 10, 5246.	1.0	2
354	The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem?. Immunotherapy, 2022, , .	1.0	2
355	HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapy. Anticancer Research, 2013, 33, 3705-10.	0.5	2
356	E-041â€…Use of Flow Diverters in the Endovascular Reconstruction of Fusiform Dissecting Vertebral Artery Aneurysms. Journal of NeuroInterventional Surgery, 2014, 6, A56.2-A57.	2.0	1
357	P-007â€…Incidence and Management of Intimal Hyperplasia at 6 months after Flow Diversion for Intracranial Aneurysms. Journal of NeuroInterventional Surgery, 2014, 6, A24.1-A24.	2.0	1
358	Acquired hemophagocytic syndrome: comment to the case report. Future Science OA, 2015, 1, FSO31.	0.9	1
359	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. Anti-Cancer Drugs, 2015, 26, 469-473.	0.7	1
360	Kidney cancer and 2014: is innovation really over?. Future Oncology, 2015, 11, 1437-1449.	1.1	1

#	Article	IF	Citations
361	Endovascular Treatment of Cerebral Aneurysms. , 2016, , 1071-1088.e6.		1
362	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790â€“807. European Urology, 2017, 72, e139-e141.	0.9	1
363	Prospects for precision therapy of bladder urothelial carcinoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 261-274.	0.4	1
364	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111â€“28. European Urology Oncology, 2019, 2, 603-604.	2.6	1
365	E-112â€…How do clots respond to direct aspiration during interventional treatment of acute ischemic stroke. , 2019, , .		1
366	Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patientsâ€™ care. Future Oncology, 2020, 16, 1413-1415.	1.1	1
367	Renal Cell Carcinoma: genomic landscape and clinical implications. Expert Review of Precision Medicine and Drug Development, 2020, 5, 95-100.	0.4	1
368	Re: Alfonso GÃ³mez de LiaÃ±o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Antiâ€“PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269â€“76. European Urology, 2021, 79, e17-e19.	0.9	1
369	Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. Pathology Research and Practice, 2021, 220, 153410.	1.0	1
370	Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. BJU International, 2021, 128, 254-261.	1.3	1
371	E-123â€…Evaluation of safety and efficacy of transradial access for mechanical thrombectomy inacute ischemic stroke â€“ A single center experience. , 2021, , .		1
372	E-120â€…First pass efficacy of anterior circulation thrombectomy using the walrus balloon guide catheter. , 2021, , .		1
373	Re: Thomas Powles, Tibor CsÅ‘szi, Mustafa Ã–zgÃ¼roÄŸlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2. European Urology Oncology, 2021, 4, 854.	2.6	1
374	Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice.. Journal of Clinical Oncology, 2012, 30, e14661-e14661.	0.8	1
375	Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.. Journal of Clinical Oncology, 2014, 32, e16058-e16058.	0.8	1
376	Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.. Journal of Clinical Oncology, 2014, 32, 253-253.	0.8	1
377	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology, 2015, 33, e15594-e15594.	0.8	1
378	Targeted agents (TA) for advanced solid tumors (AST): What is the likelihood of being helped or harmed (LHH)? Assessing the clinical impact of therapies with FDA/EMEA approval.. Journal of Clinical Oncology, 2013, 31, e17555-e17555.	0.8	1

#	Article	IF	Citations
379	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. Journal of Clinical Oncology, 2016, 34, 547-547.	0.8	1
380	Immune checkpoint inhibitors for metastatic bladder cancer. Translational Cancer Research, 2017, 6, S720-S732.	0.4	1
381	Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Annals of Translational Medicine, 2019, 7, S194-S194.	0.7	1
382	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. Journal of Clinical Oncology, 2020, 38, TPS762-TPS762.	0.8	1
383	Improving IMDC criteria in patients with metastatic renal cell carcinoma through the addition of initial metastatic site in bone, brain, and liver.. Journal of Clinical Oncology, 2020, 38, 754-754.	0.8	1
384	Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?. Pathology Research and Practice, 2022, 234, 153937.	1.0	1
385	Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori, 2023, 109, 157-163.	0.6	1
386	E-044â€…Percutaneous image guided c-spine procedures. Journal of NeuroInterventional Surgery, 2012, 4, A65.1-A65.	2.0	0
387	E-043â€…Image guided sympathetic blocks. Journal of NeuroInterventional Surgery, 2012, 4, A64.2-A64.	2.0	0
388	E-042â€…Use of Flow Diverters in Vessels less than 2.5 mm during Intracranial Aneurysm Treatment. Journal of NeuroInterventional Surgery, 2014, 6, A57.1-A57.	2.0	0
389	E-131â€…endovascular reconstruction of intradural vertebral artery fusiform dissecting aneurysms with the pipeline embolization device. Journal of NeuroInterventional Surgery, 2015, 7, A101.2-A101.	2.0	0
390	P-014â€…arts (ace-retriever technique for stroke): initial clinical experience. Journal of NeuroInterventional Surgery, 2015, 7, A29.1-A29.	2.0	0
391	2-weekly docetaxel: issues for clinical practice. Cancer Biology and Therapy, 2015, 16, 17-18.	1.5	0
392	Prostate cancer grading in 2016. Minerva Urology and Nephrology, 2016, 69, 1-4.	1.3	0
393	E-091â€…Treatment of Aneurysms of the Pericallosal Artery with the Pipeline Embolization Device. Journal of NeuroInterventional Surgery, 2016, 8, A90.1-A90.	2.0	0
394	E-040â€…Five-year Single Center Experience of Intracranial Aneurysm Treatment with the PED in Patients of different Age Groups. Journal of NeuroInterventional Surgery, 2016, 8, A65.1-A65.	2.0	0
395	E-070â€…Endovascular Techniques for Achievement of Better Flow Diverter Wall Apposition. Journal of NeuroInterventional Surgery, 2016, 8, A79.1-A79.	2.0	0
396	2015 and human cancer: back to overall survival. Future Oncology, 2016, 12, 1751-1754.	1.1	0

#	Article	IF	Citations
397	Quick steps toward precision medicine in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2018, 3, 283-285.	0.4	0
398	E-034â€...Single-center experience with the celt acd vascular closure device for neurointerventional procedures. , 2018, , .		0
399	E-102â€...Use of pipeline embolization device for ICA reconstruction through false lumen. , 2018, , .		0
400	E-130â€...Thrombectomy for superior division versus inferior division MCA occlusions: recanalization rates, MTICI scores and first pass effect. , 2018, , .		0
401	Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?. Lancet Oncology, The, 2018, 19, e437.	5.1	0
402	Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462â€“8. European Urology, 2018, 74, e12-e13.	0.9	0
403	Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders. Annals of Oncology, 2019, 30, v336-v337.	0.6	0
404	Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. Annals of Oncology, 2019, 30, v368-v369.	0.6	0
405	733P Quality of life assessment in renal cell carcinoma phase II and III clinical trials published between 2010 and 2020. Annals of Oncology, 2020, 31, S573.	0.6	0
406	760P Platinum-based adjuvant chemotherapy in upper tract urothelial carcinomas (UTUCs): A change of paradigm? A meta-analysis of aggregate data. Annals of Oncology, 2020, 31, S588.	0.6	0
407	767P Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study. Annals of Oncology, 2020, 31, S592.	0.6	0
408	Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038. European Urology Oncology, 2020, 3, 559-560.	2.6	0
409	Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study. Diagnostics, 2021, 11, 184.	1.3	0
410	O-015â€...Assessment of thrombectomy procedure difficulty by neurointerventionalists based on vessel geometry parameters from carotid artery 3D reconstructions. , 2021, , .		0
411	Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology, 2021, 7, 1068.	3.4	0
412	E-122â€...Incidence of access site complications after transradial access for neurointerventions. , 2021, , .		0
413	E-118â€...Minimally invasive fluproscopy-guided percutaneous bleomycin sclerotherapy for craniofacial venolymphatic malformations in children. , 2021, , .		0
414	E-053â€...Mount everest technique (MET) with the novel tenzing inserts and super large bore catheters â€“ Technique and initial experience. , 2021, , .		0

#	Article	IF	Citations
415	E-119â€...Anatomical snuffbox access (Distal Radial Artery) for carotid artery stenting. , 2021, , .		0
416	E-117â€...Evaluation of patient deaths after mechanical thrombectomy â€“ A single center experience. , 2021, , .		0
417	E-121â€...Evaluation of safety and efficacy of snuffbox (Distal Radial Artery) access for mechanical thrombectomy in acute ischemic stroke. , 2021, , .		0
418	Randomized Clinical Trials in the Era of Precision Oncologyâ€"The Role of End Points, Industry Funding, and Medical Writing Integrity. JAMA Oncology, 2021, 7, 1577.	3.4	0
419	EP42*â€...Use of the new philipsÂ´advanced 3D neuro-imaging for LVO triaging and door to puncture times reduction. , 2021, , .		0
420	1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: A systematic review and meta-analysis. Annals of Oncology, 2021, 32, S1239.	0.6	0
421	Early evaluation of response to neoadjuvant chemotherapy in stage IIIC-IV epithelial ovarian cancer patients by 18FDG-PET and CA 125: Preliminary findings from the Arianna Project 02. Journal of Clinical Oncology, 2006, 24, 15039-15039.	0.8	0
422	Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials.. Journal of Clinical Oncology, 2012, 30, 630-630.	0.8	0
423	How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients.. Journal of Clinical Oncology, 2013, 31, e16053-e16053.	0.8	0
424	Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. Journal of Clinical Oncology, 2014, 32, 214-214.	0.8	0
425	Prognostic value of flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib (PA) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, 448-448.	0.8	0
426	Suitability of clear cell renal cell carcinoma to heat shock proteins-inhibitors.. Journal of Clinical Oncology, 2014, 32, 480-480.	0.8	0
427	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 421-421.	0.8	0
428	Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma.. Journal of Clinical Oncology, 2014, 32, 374-374.	0.8	0
429	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. Journal of Clinical Oncology, 2014, 32, e15568-e15568.	0.8	0
430	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. Journal of Clinical Oncology, 2014, 32, e15588-e15588.	0.8	0
431	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. Journal of Clinical Oncology, 2015, 33, 206-206.	0.8	0
432	Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. Journal of Clinical Oncology, 2015, 33, e15595-e15595.	0.8	0

#	Article	IF	Citations
433	Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, 553-553.	0.8	0
434	Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?. Journal of Clinical Oncology, 2016, 34, 549-549.	0.8	0
435	Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 231-231.	0.8	0
436	mTOR Pathway in Renal Cell Carcinoma. , 2016, , 417-428.		0
437	Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.. Journal of Clinical Oncology, 2016, 34, 342-342.	0.8	0
438	PRO-BMI study: prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy.. Journal of Clinical Oncology, 2016, 34, e16543-e16543.	0.8	0
439	Is there still an open window in metastatic castration resistant prostate cancer immunotherapy horizon?. Translational Cancer Research, 2016, 5, S1061-S1065.	0.4	0
440	Localized prostate cancer genotyping: another step towards personalized therapy. Translational Cancer Research, 2017, 6, S246-S248.	0.4	0
441	E-016â€...Angioplasty following pipeline embolization device delivery safely improves the midterm angiographic outcome. , 2018, , .		0
442	E-019â€...Initial post market experience with the pulserider intracranial stent. , 2018, , .		0
443	Adjuvant therapy in renal cell carcinomaâ€"is pharmacogenomics assessment another element to select our patients?. Annals of Translational Medicine, 2019, 7, S38-S38.	0.7	0
444	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2019, 37, 572-572.	0.8	0
445	Optimizing renal function and outcome of patients with cT2 renal cell carcinoma. Annals of Translational Medicine, 2019, 7, S39-S39.	0.7	0
446	N-Myc a key gene promoting a worst prostate cancer progression. Translational Cancer Research, 2019, 8, E15-E17.	0.4	0
447	Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study.. Journal of Clinical Oncology, 2020, 38, 632-632.	0.8	0
448	Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2020, 38, e15080-e15080.	0.8	0
449	Baseline and early change of neutrophil to lymphocyte ratio (bNLR and Î"NLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. Journal of Clinical Oncology, 2020, 38, e17081-e17081.	0.8	0
450	Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).. Journal of Clinical Oncology, 2020, 38, 701-701.	0.8	0

#	Article	IF	Citations
451	Acutely Symptomatic Hypoperfusion Through an Occluded Subclavian to Internal Carotid Artery Bypass Graft: Salvage Mechanical Thrombectomy and Graft Revascularization. Cureus, 2022, 14, e20881.	0.2	0
452	CAREâ€'compliant stereotactic radiotherapy of urothelial nodal metastases: A case report. Molecular and Clinical Oncology, 2022, 16, 85.	0.4	0
453	Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncology, 2022, , .	3.4	0